Skip to main content

Table 4 Concordance of subtype calls and risk categories between the three sites

From: Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens

Comparison type

Pairwise Concordance [95% CI]

Average concordance

Site 1 vs. Site 2

Site 1 vs. Site 3

Site 2 vs. Site 3

(n = 40)

(n = 41)

(n = 40)

Subtype

96.3%

98.8%

95%

97%

[86.4%–99.5%]

[91.0%–100%]

[83.1%–99.3%]

Risk Category

87.5%

92.7%

90%

90%

(Node Negative)

[73.2%–95.8%]

[80.1%–98.4%]

[76.4%–97.2%]

Risk Category

90.0%

95.1%

95.0%

93%

(Node Positive)

[76.9%–96.0%]

[83.9%–98.7%]

[83.5%–98.6%]

  1. The pairwise (site to site) concordance is reported with the 95% confidence interval.